HPV16+ Cancer Pipeline Drugs Report 2025: Emerging Therapies, Clinical Trials, and Market Insights by DelveInsight

DelveInsight's, "Human papillomavirus 16-positive (HPV16+) cancers Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Human papillomavirus 16-positive (HPV16+) cancers pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight's comprehensive HPV16+ Cancer Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ HPV16+ Cancer Pipeline Outlook Report- https://www.delveinsight.com/sample-request/human-papillomavirus-16-positive-hpv16-cancers-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the HPV16+ Cancer Pipeline Report
• In June 2025, Yonsei University announced a study is open label, phase II clinical trial for the Combination of GX-188E HPV DNA Vaccine with GX-I7 or Pembrolizumab OR the Triple Combination of GX-188E HPV DNA Vaccine, GX-I7, and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 or 18 Positive Head and Neck Cancer.
• In June 2025, BioNTech SE conducted a Phase II/III trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in patients with unresectable recurrent or metastatic HPV16+ Cancer expressing programmed cell death ligand-1 (PD-L1) with combined positive score (CPS) ≥1.
• In June 2025, PDS Biotechnology Corp. organized Phase 3 study that is randomized 2:1, controlled, and open label to evaluate PDS0101 (Versamune + HPVMix) in combination with pembrolizumab vs. pembrolizumab monotherapy as first-line treatment in patients with unresectable recurrent or metastatic HPV16-positive HNSCC expressing programmed cell death ligand-1 (PD-L1) with combined positive score (CPS) ≥1.
• DelveInsight's HPV16+ Cancer pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for HPV16+ Cancer treatment.
• The leading HPV16+ Cancer Companies such as ISA Pharmaceuticals, Cue Biopharma, Genexine, Vaccibody AS, PDS Biotechnology, BlueSky Immunotherapies GmbH and others.
• Promising HPV16+ Cancer Pipeline Therapies such as Aldesleukin, Pembrolizumab, Cisplatin, PDS0101, BNT113, CUE-101, and others.

Discover how the HPV16+ Cancer treatment paradigm is evolving. Access DelveInsight's in-depth HPV16+ Cancer Pipeline Analysis for a closer look at promising breakthroughs @ HPV16+ Cancer Clinical Trials and Studies- https://www.delveinsight.com/sample-request/human-papillomavirus-16-positive-hpv16-cancers-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

HPV16+ Cancer Emerging Drugs Profile

• ISA101b: ISA Pharmaceuticals
ISA101b consists of 12 synthetic long peptides derived from the E6 and E7 oncogenic proteins of the HPV 16 virus, a strain responsible for over 50% of human cervical cancers and cervical intra-epithelial neoplasias, more than 85% of HPV-positive head and neck cancers, and similar substantial percentages of other premalignant and malignant HPV-induced lesions (such as VIN, vulvar cancer, AIN and anal cancer). It is currently administered either subcutaneously or intradermally. ISA101 has completed a Phase II trial in vulvar intra-epithelial neoplasia, establishing clinical proof-of-concept. In cervical cancer, ISA101 has successfully completed a company-sponsored Phase I/II trial and has entered into further clinical development in collaboration with Regeneron. The alliance aims to develop and advance ISA101 in combination with cemiplimab (Libtayo®), a PD-1 (programmed cell death protein 1) antibody currently under review by EMA and initially approved by the U.S. Food and Drug Administration in September 2018 under the brand name Libtayo® as monotherapy for patients with advanced cutaneous squamous cell carcinoma. Currently, the drug is in Phase II stage of its development for the treatment of HPV16-Positive Oropharyngeal Cancer (OPC).

• CUE-101: Cue Biopharma
The CUE-100 series of biologics have the potential to improve efficacy and reduce the severe toxicities associated with non-specific IL-2 cancer immunotherapies. They are engineered to selectively engage and modulate tumor-specific immune T cells by taking advantage of the specificity already existing in nature, and avoid toxicities associated with indiscriminate immune activation. CUE-101, has already demonstrated clinical activity and favorable tolerability as a monotherapy in a Phase I trial in patients with human papilloma virus (HPV16+) recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). This validates the clinical applicability of our technology platforms and therapeutic potential of our advanced pipeline of biologics for the treatment of cancer. Currently, the drug is in Phase II stage of its development for the treatment of Oropharyngeal Squamous Cell Carcinoma.

The HPV16+ Cancer Pipeline Report Provides Insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of HPV16+ Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HPV16+ Cancer Treatment.
• HPV16+ Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• HPV16+ Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the HPV16+ Cancer market

Explore groundbreaking therapies and clinical trials in the HPV16+ Cancer Pipeline. Access DelveInsight's detailed report now! @ New HPV16+ Cancer Drugs- https://www.delveinsight.com/sample-request/human-papillomavirus-16-positive-hpv16-cancers-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

HPV16+ Cancer Companies
ISA Pharmaceuticals, Cue Biopharma, Genexine, Vaccibody AS, PDS Biotechnology, BlueSky Immunotherapies GmbH and others.

Human papillomavirus 16-positive (HPV16+) cancers pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

HPV16+ Cancer Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key developments @ HPV16+ Cancer Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/human-papillomavirus-16-positive-hpv16-cancers-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the HPV16+ Cancer Pipeline Report
• Coverage- Global
• HPV16+ Cancer Companies- ISA Pharmaceuticals, Cue Biopharma, Genexine, Vaccibody AS, PDS Biotechnology, BlueSky Immunotherapies GmbH and others.
• HPV16+ Cancer Pipeline Therapies- Aldesleukin, Pembrolizumab, Cisplatin, PDS0101, BNT113, CUE-101, and others.
• HPV16+ Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• HPV16+ Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in HPV16+ Cancer Drug Development? Find out in DelveInsight's exclusive HPV16+ Cancer Pipeline Report-access it now! @ HPV16+ Cancer Emerging Drugs and Major Companies- https://www.delveinsight.com/sample-request/human-papillomavirus-16-positive-hpv16-cancers-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. Human papillomavirus 16-positive (HPV16+) cancers: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Human papillomavirus 16-positive (HPV16+) cancers - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug Name: Company Name
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. ISA101b: ISA Pharmaceuticals
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I/II)
14. Drug Name: Company Name
15. Drug profiles in the detailed report.....
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report.....
19. Inactive Products
20. Human papillomavirus 16-positive (HPV16+) cancers Key Companies
21. Human papillomavirus 16-positive (HPV16+) cancers Key Products
22. Human papillomavirus 16-positive (HPV16+) cancers- Unmet Needs
23. Human papillomavirus 16-positive (HPV16+) cancers- Market Drivers and Barriers
24. Human papillomavirus 16-positive (HPV16+) cancers- Future Perspectives and Conclusion
25. Human papillomavirus 16-positive (HPV16+) cancers Analyst Views
26. Human papillomavirus 16-positive (HPV16+) cancers Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.